THOUSAND OAKS, Calif.,
Sept. 25, 2019 /PRNewswire/
-- Amgen (NASDAQ:AMGN) will host a webcast call for the
investment community in conjunction with the European Society for
Medical Oncology (ESMO) 2019 Congress on Saturday, Sept. 28, at 10
a.m. PT. David M. Reese,
M.D., executive vice president of Research and Development at
Amgen, along with members of Amgen's clinical development team,
will participate to discuss Amgen's oncology program, including
data being presented at ESMO for the Company's KRASG12C
inhibitor AMG 510.
Live audio of the investor call will be broadcast over the
internet simultaneously and will be available to members of the
news media, investors and the general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given at certain investor and
medical conferences, can be accessed on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the
event.
About Amgen
Amgen is committed to unlocking
the potential of biology for patients suffering from serious
illnesses by discovering, developing, manufacturing and delivering
innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease
and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and
leverages its expertise to strive for solutions that improve health
outcomes and dramatically improve people's lives. A biotechnology
pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand
Oaks
Jessica Akopyan, 805-447-0974
(media)
Trish Hawkins, 805-447-5631
(media)
Arvind Sood, 805-447-1060
(investors)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-esmo-2019-300924835.html
SOURCE Amgen